antihemophilic factor

Antihemophilic factor, also known as Coagulation Factor VIII (FVIII), is an essential blood-clotting protein used for the treatment and prophylaxis of bleeding episodes in patients with Hemophilia A. In the specific context of research conducted by **The Hospital for Sick Children (SickKids)**, a "once-daily low-dose" prophylaxis regimen was investigated in youth and young adults with severe Hemophilia A. This protocol involves the daily administration of FVIII (using various commercial preparations such as Advate, Kogenate FS, or Recombinate) at doses of 250 or 500 units to maintain consistent factor levels and prevent spontaneous joint bleeds. Biologically, FVIII functions as a critical cofactor for activated Factor IX (FIXa) in the intrinsic pathway of the coagulation cascade. Together with FIXa, calcium, and phospholipids, it forms the tenase complex, which activates Factor X, ultimately leading to thrombin generation and the formation of a stable fibrin clot.

Brand names

Kogenate FSAdvateHumate-PRecombinateHelixate FS

Other names

antihemophilic factor (recombinant)antihemophilic factor (human)coagulation factor VIII (recombinant)coagulation factor VIII (human)